


Figure. Study Design



Primary endpoint: safety (AEs, MTD/RP2D)

Secondary endpoints: pharmacokinetics, immunogenicity (frequency of ADAs), and efficacy

2L, second line; 4L, fourth line; ADA, antidrug antibody; AE, adverse event; GIST, gastrointestinal stromal tumor; IDH, isocitrate dehydrogenase; MTD, maximum tolerated dose; RP2D, recommended phase 2 dose; SDH, succinate dehydrogenase.